A clinical efficacy study of an oral tyrosine kinase inhibitor of VEGFR-2 given in combination with chemotherapy (paclitaxel and carboplatin) vs. chemotherapy alone for the treatment of advanced stage non-small cell lung cancer

Trial Profile

A clinical efficacy study of an oral tyrosine kinase inhibitor of VEGFR-2 given in combination with chemotherapy (paclitaxel and carboplatin) vs. chemotherapy alone for the treatment of advanced stage non-small cell lung cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2007

At a glance

  • Drugs PAN 90806 (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 10 Aug 2006 Status change
    • 03 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top